Autoantibodies are a subset of antibodies that target the body’s own molecules and can be either protective or pathogenic. While traditionally linked to autoimmune diseases, they are also significant in a variety of conditions, including cancer and neurological disorders. Sengenics’ protein microarrays enable precise profiling of antibodies and autoantibodies through ready-to-use panels or customizable options.
Antibodies are generated through specific mechanisms linked to pathological processes, making them biologically relevant and timely biomarkers. They excel at identifying disease-associated proteins, offering key insights into disease mechanisms and highlighting potential targets for drug development. With exceptional sensitivity and specificity, antibodies bind to their targets and are often found in high concentrations in patient sera, allowing for easy collection and measurement in small sample volumes. By combining multiple antibodies into a biomarker panel or signature, researchers gain powerful tools for predicting disease onset, monitoring progression, and guiding therapeutic decisions.
Unlike traditional biomarkers like proteins or genomic markers, which provide only a brief snapshot, antibodies offer real-time insights into a patient’s health. Often appearing years before symptoms and persisting throughout disease progression, antibodies reflect disease severity and treatment response. This gives them transformative potential for early diagnosis, continuous disease monitoring, and accurate outcome prediction—unlocking new possibilities for timely interventions and personalized care.
